B4GALNT2 catalyzes the last step in the biosynthesis of the human Sd(a) antigen through the addition of an N-acetylgalactosamine residue via a beta-1,4 linkage to a subterminal galactose residue substituted with an alpha-2,3-linked sialic acid. B4GALNT2 also catalyzes the last step in the biosynthesis of the Cad antigen. The longer transcript encodes a deduced 566-amino acid protein with a calculated molecular mass of 63.3 kD. It contains an N-terminal cytosolic domain, followed by a transmembrane domain and a long catalytic domain. The shorter transcript encodes a deduced 506-amino acid protein with calculated molecular mass of 57.0 kD. It has a different N-terminal cytosolic domain than the full-length form. Northern blot analysis detected B4GALNT2 transcripts of 8.8, 6.1, 4.7, 3.8, and 1.65 kb.

Human Salivary duct autoantibody (SDA) ELISA Kit has been pre-coated with an antibody specific to SDA. Standards or samples are then added to the appropriate microtiter plate wells with a Horseradish Peroxidase (HRP)-conjugated SDA and incubated. The competitive inhibition reaction is launched between with HRP labeled SDA and unlabeled SDA with the antibody. A substrate solution is added to the wells and the color develops in opposite to the amount of SDA in the sample. The color development is stopped and the intensity of the color is measured.

Human Salivary duct autoantibody (SDA) ELISA Kit listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Find more details at http://www.abbkine.com/product/human-salivary-duct-autoantibody-sda-elisa-kit-kte62483/

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.